Descripción de la empresa
Astrana Health, Inc. operates as a healthcare management entity delivering essential medical care services throughout the United States. The organization executes its operations across three distinct segments known as Care Partners, Care Delivery, and Care Enablement, focusing on care coordination services for patients, families, primary care physicians, and other stakeholders. This enterprise is situated within the broader Healthcare sector and specifically functions in the Medical Care Facilities industry, positioning it as a provider of integrated care solutions. Astrana Health, Inc. currently maintains a market capitalization of $1.54 billion, supported by annual revenue of $3.18 billion and an employee base of 3,000 individuals. These valuation and revenue figures indicate that the company holds a significant position within its niche, reflecting a substantial asset base and operational scale that allows for extensive service delivery.
Salud financiera
The company reported a total revenue of $3.18 billion over the trailing twelve months, generating net income of $22.49 million and an EBITDA of $143.87 million during the same period. The substantial gap between the $3.18 billion revenue and the $22.49 million net income reveals a cost structure where operating expenses heavily impact the bottom line, resulting in thin profitability relative to top-line growth. Free cash flow stands at $227.95 million, which provides the company with considerable financial flexibility to fund operations, service debt, or pursue strategic initiatives without immediate external capital reliance. When analyzing profitability margins, the gross margin is recorded at 10.7%, the operating margin sits at 1.9%, and the profit margin is 0.7%, indicating that the business model relies on high volume rather than high per-unit pricing power to generate earnings. Regarding capital structure, total cash holdings of $429.59 million are compared against total debt of $1.08 billion, yielding a debt-to-equity ratio of 193.10%, which suggests a highly leveraged balance sheet rather than a conservative one. Liquidity is assessed via a current ratio of 1.40, indicating that the company possesses 40% more current assets than current liabilities, providing a moderate buffer for short-term obligations. Return on equity is calculated at 4.5% while return on assets is 3.4%, metrics that reveal that management effectiveness in generating returns on the capital invested is currently limited by the high leverage and low profit margins.
Evaluación de valoración
The trailing twelve-month P/E ratio is 56.63, whereas the forward P/E is 9.28, implying that the market currently prices the stock at a significant premium relative to historical earnings but expects a substantial multiple compression or earnings explosion to justify the forward multiple. The price-to-book ratio stands at 1.74, indicating that the market values the company at a 74% premium over its net asset book value, reflecting investor expectations for future growth that are not yet realized in current earnings. Alternative valuation metrics include a price-to-sales ratio of 0.48 and an EV/EBITDA of 12.51, suggesting that despite high earnings multiples, the stock trades at a low multiple relative to its sales and adjusted earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $34.80 and a 52-week low of $18.08, and without the current specific share price, the precise percentage distance from the high cannot be calculated from the provided data alone, though the wide range indicates high volatility in recent trading sessions. The beta value is 0.77, which means the stock price exhibits lower volatility relative to the broader market, moving roughly 23% less than the market average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is reported at 42.9%, while earnings growth for the year is listed as N/A, indicating that profitability has not yet scaled proportionally with the top-line expansion. The absence of earnings growth data suggests that the company is still in a phase where revenue expansion is prioritizing market share or operational scaling over immediate profit margin improvement. Astrana Health, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings back into the business rather than distributing cash to shareholders. This reinvestment strategy supports the high revenue growth rate of 42.9% by funding the expansion of medical care facilities and care coordination services across its three segments. Overall, the growth and income profile is characterized by aggressive revenue expansion and a complete lack of dividend distribution, focusing entirely on capital deployment for organic growth.